Novo Nordisk stated Wednesday that it’s going to work with the biotech Septerna to develop oral GLP-1 weight problems medication, because it races to catch as much as competitor Eli Lilly’s efforts to deliver a extra handy weight reduction remedy to the market.
Below the deal, Septerna, which focuses on making small molecule medication, is eligible to obtain about $2.2 billion from Novo, together with greater than $200 million in upfront and near-term milestone funds. Septerna, which relies within the San Francisco space, might additionally obtain royalties on international gross sales of permitted merchandise.
The businesses stated they’ll begin with 4 growth packages for potential small molecule remedies directed at targets inside a category of receptor referred to as G protein-coupled receptors. They embody generally focused receptors like GLP-1, GIP, and glucagon hormone receptors.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
